These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 4218337)

  • 1. Reversal by Pseudomonas aeruginosa of rifamycin SV inhibition of Staphylococcus aureus in vitro and in vivo.
    De Repentigny J; Mathieu LG
    Rev Can Biol; 1974 Dec; 33(4):239-42. PubMed ID: 4218337
    [No Abstract]   [Full Text] [Related]  

  • 2. [The antibacterial and chemotherapeutic activity of the Soviet produced antibiotic rifamitsina SV].
    Shorin VA; Shapovalova SP
    Antibiotiki; 1974 Jan; 19(1):3-6. PubMed ID: 4156904
    [No Abstract]   [Full Text] [Related]  

  • 3. Oximes of 3-formylrifamycin SV. Synthesis, antibacterial activity, and other biological properties.
    Cricchio R; Lancini G; Tamborini G; Sensi P
    J Med Chem; 1974 Apr; 17(4):396-403. PubMed ID: 4151507
    [No Abstract]   [Full Text] [Related]  

  • 4. [Diminution of the antibacterial activity of antibiotics in cultures and in experimental mixed infections].
    Lebrun M; de Repentigny J; Mathieu LG
    Can J Microbiol; 1978 Feb; 24(2):154-61. PubMed ID: 417782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antibiotic sensitivity of the main opportunistic pathogenic aerobic bacteria].
    Minukhin VV; Tsyganenko AIa; Kravtsova VI; Arkushenko LL; Stepanenko TV
    Antibiot Khimioter; 1990 Mar; 35(3):36-8. PubMed ID: 2113800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic wound infections: the role of Pseudomonas aeruginosa and Staphylococcus aureus.
    Serra R; Grande R; Butrico L; Rossi A; Settimio UF; Caroleo B; Amato B; Gallelli L; de Franciscis S
    Expert Rev Anti Infect Ther; 2015 May; 13(5):605-13. PubMed ID: 25746414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus.
    Murphy CK; Mullin S; Osburne MS; van Duzer J; Siedlecki J; Yu X; Kerstein K; Cynamon M; Rothstein DM
    Antimicrob Agents Chemother; 2006 Mar; 50(3):827-34. PubMed ID: 16495239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of acetoxan and prodigiozan in combination with antibiotics in mixed purulent infection].
    Vaĭsberg GE; Taranenko LA
    Antibiotiki; 1967 Aug; 12(8):680-4. PubMed ID: 4297667
    [No Abstract]   [Full Text] [Related]  

  • 9. [RIFAMYCIN SV: ITS ACTIVITY "IN VITRO" ON STAPHYLOCOCCUS AUREUS].
    NOTA NR; NEMJAMKIS M; FRIGERIO J
    Dia Med; 1963 Sep; 35():1419-20. PubMed ID: 14090641
    [No Abstract]   [Full Text] [Related]  

  • 10. [Characteristics of current antibiotic therapy].
    Navashin SM; Fomina IP
    Klin Med (Mosk); 1979 Jul; 57(7):10-23. PubMed ID: 113612
    [No Abstract]   [Full Text] [Related]  

  • 11. [IN VITRO EXPERIMENT WITH RIFAMYCIN SV AGAINST STAPHYLOCOCCUS AUREUS].
    LINZENMEIER G
    Chemotherapia (Basel); 1963; 27():236-41. PubMed ID: 14128781
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence of inoculum size of Staphylococcus aureus and Pseudomonas aeruginosa on in vitro activities and in vivo efficacy of fluoroquinolones and carbapenems.
    Mizunaga S; Kamiyama T; Fukuda Y; Takahata M; Mitsuyama J
    J Antimicrob Chemother; 2005 Jul; 56(1):91-6. PubMed ID: 15890721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on new antibiotic lividomycins. V. In vitro and in vivo antimicrobial activity of lividomycin A.
    Kobayashi F; Nagoya T; Yoshimura Y; Kaneko K; Ogata SI
    J Antibiot (Tokyo); 1972 Feb; 25(2):128-36. PubMed ID: 4624613
    [No Abstract]   [Full Text] [Related]  

  • 14. Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use.
    MacDougall C; Harpe SE; Powell JP; Johnson CK; Edmond MB; Polk RE
    Emerg Infect Dis; 2005 Aug; 11(8):1197-204. PubMed ID: 16102307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antibacterial activity of a new 3-azinomethyl-rifamycin.
    Strippoli V; Bruzzese T; Galli R; Simonetti N; Tronci N
    Farmaco Sci; 1988; 43(7-8):619-25. PubMed ID: 3147199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapies against virulence products of Staphylococcus aureus and Pseudomonas aeruginosa.
    Wiener-Kronish JP; Pittet JF
    Semin Respir Crit Care Med; 2011 Apr; 32(2):228-35. PubMed ID: 21506059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Aztreonam].
    Iakovlev VP
    Antibiot Khimioter; 1992 Aug; 37(8):49-56. PubMed ID: 1456829
    [No Abstract]   [Full Text] [Related]  

  • 18. [Interactions between Staphylococcus aureus and Pseudomonas aeruginsa in cultures in vitro and in the course of experimental infections].
    de Repentigny J; Mathieu LG; Gadbois T
    Can J Microbiol; 1972 Oct; 18(10):1531-41. PubMed ID: 4628183
    [No Abstract]   [Full Text] [Related]  

  • 19. Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010.
    Nordmann P; Naas T; Fortineau N; Poirel L
    Curr Opin Microbiol; 2007 Oct; 10(5):436-40. PubMed ID: 17765004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of topical chlorhexidine, ciprofloxacin, and fortified tobramycin/cefazolin in rabbit models of Staphylococcus and Pseudomonas keratitis.
    Bu P; Riske PS; Zaya NE; Carey R; Bouchard CS
    J Ocul Pharmacol Ther; 2007 Jun; 23(3):213-20. PubMed ID: 17593004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.